Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Peripheral T-cell lymphoma (PTCL) is a diverse group of mature T-cell cancers.
• The T-cell receptor (TCR) signaling pathway is crucial for T-cell function and is frequently altered in PTCL.

Purpose of the Study:

• To review genetic alterations in the proximal TCR signaling pathway across PTCL subgroups.
• To examine the functional impact of these genetic changes on TCR signaling and downstream pathways.
• To highlight potential therapeutic targets and ongoing clinical trials for PTCL.

Main Methods:

• Review of preclinical and clinical studies identifying genetic alterations in PTCL.
• Analysis of gene mutations, indels, and fusions within the proximal TCR signaling pathway.
• Focus on molecular pathology of PTCL-NOS and PTCL-GATA3 subgroups.

Main Results:

• Identified recurrent activating mutations and gene fusions in genes such as CD28, CARD11, RHOA, VAV1, FYN, ITK, PLCG1, PKCB, and PI3K subunits.
• These genetic abnormalities predominantly manifest as activating mutations.
• These mutations offer potential targets for novel therapeutic inhibitors.

Conclusions:

• Genetic alterations in proximal TCR signaling are a hallmark of various PTCL subtypes.
• These aberrations provide a rationale for targeted inhibitor therapies.
• Ongoing clinical trials are exploring the efficacy of these targeted agents in PTCL treatment.